Medyczne Centrum Hetmanska
- Address
- lock Available on a paid plan
Immune System Diseases
At Medyczne Centrum Hetmanska in Poznan, a large share of the research focuses on immune system diseases, especially systemic lupus erythematosus, lupus nephritis, and psoriatic arthritis. These studies are designed to test new treatment options, measure how well they control disease activity, and assess long-term safety.
- Systemic lupus erythematosus and related forms, with a focus on improving disease control and response rates
- Lupus nephritis, studying treatments aimed at protecting kidney function
- Psoriatic arthritis, including therapies for active disease and biologic-naive patients
The site is also involved in research on immune system processes, reflecting interest in how these conditions develop and how treatment response can be better understood.
Musculoskeletal Diseases
Research in musculoskeletal diseases at this health care site includes rheumatoid arthritis, axial spondyloarthritis, and knee osteoarthritis. The trials aim to evaluate whether new therapies can reduce pain, improve mobility, and provide better symptom relief for people living with chronic joint disease.
- Rheumatoid arthritis, including studies in newly diagnosed and moderately active disease
- Axial spondyloarthritis, with attention to long-term safety and tolerability of treatment
- Knee osteoarthritis, focusing on pain reduction and functional improvement
This work shows a strong emphasis on both inflammatory joint disorders and degenerative joint disease, with the goal of improving everyday quality of life.
Skin and Connective Tissue Diseases
The research portfolio also covers skin and connective tissue diseases, including systemic sclerosis and related autoimmune conditions. Studies in this area are exploring whether new treatments can slow disease progression, ease symptoms, and improve organ-related outcomes such as lung function.
- Systemic sclerosis, with interest in broader symptom control and organ protection
- Autoimmune connective tissue disease research linked to lupus and inflammatory overlap conditions
- Therapies intended to improve long-term disease management and patient outcomes
The Poznan site contributes to research that aims to expand treatment choices for complex autoimmune disorders affecting the skin and connective tissues.
Nutritional and Metabolic Diseases
In the area of nutritional and metabolic diseases, the site is studying obesity, often alongside knee osteoarthritis. These trials are focused on evaluating whether new approaches can support weight reduction and help relieve joint pain, especially in people whose mobility is affected by excess body weight.
- Obesity, with research aimed at improving weight-related health outcomes
- Osteoarthritis linked to obesity, examining pain and functional symptoms
- Supportive treatment strategies that combine symptom relief with broader metabolic health goals
This adds a practical prevention and symptom-management dimension to the broader autoimmune and rheumatology research at Medyczne Centrum Hetmanska.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medyczne Centrum Hetmanska
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus | Bristol Myers Squibb International Corporation | Phase II | Not Recruiting | May 2019 | Mar 2025 |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Deucravacitinib | 3 | Unknown | 2019-05-28 | 2023-05-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.